safinamide has been researched along with rasagiline in 27 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (rasagiline) | Trials (rasagiline) | Recent Studies (post-2010) (rasagiline) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 535 | 72 | 314 |
| Protein | Taxonomy | safinamide (IC50) | rasagiline (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 2.3865 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 1.0029 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.2115 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 1.088 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.019 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.2217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 15 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Alcaro, S; Borges, F; Cagide, F; Chavarria, D; Fernandes, C; Gaspar, A; Ortuso, F; Reis, J; Remião, F; Silva, T; Uriarte, E | 1 |
| Kim, YS; Lee, J; Lee, Y; Park, SJ; Suh, YG | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Fonseca, A; Matos, MJ; Ortuso, F; Reis, J; Silva, T; Uriarte, E | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Bajda, M; Cichoń, U; Doroz-Płonka, A; Kaleta, M; Karcz, T; Kieć-Kononowicz, K; Kuder, K; Olejarz-Maciej, A; Siwek, A; Łażewska, D | 1 |
| Antonov, L; Atanasov, AG; Hristova, S; Stammler, HG; Tzvetkov, NT | 1 |
| Antonov, L; Atanasov, AG; Balacheva, AA; Faraone, I; Gastreich, M; Georgieva, MG; Hristova, S; Milella, L; Russo, D; Stammler, HG; Tzvetkov, NT | 1 |
| Borges, F; Chavarria, D; Fernandes, C; Gil-Martins, E; Oliveira, PJ; Remião, F; Silva, C; Silva, R; Silva, T; Silva, V; Soares, P | 1 |
| Abarbri, M; El Qami, A; Frlan, R; Gobec, S; Jismy, B; Knez, D; Kos, J; Pišlar, A | 1 |
| Alcaro, S; Borges, F; Fernandes, C; Gaspar, A; Maruca, A; Mesiti, F; Remião, F; Rocca, R; Silva, V; Uriarte, E | 1 |
| Duan, Y; Han, J; Hou, R; Kong, H; Liao, C; Meng, X; Xie, Z; Yang, X | 1 |
| Alcaro, S; Barreiro, S; Borges, F; Chavarria, D; Fernandes, C; Gaspar, A; Gil Martins, E; Gul, S; Keminer, O; Maruca, A; Mesiti, F; Rocca, R; Silva, R | 1 |
| Blicharz, K; Bojarski, AJ; Doroz-Płonka, A; Grychowska, K; Jastrzębska-Więsek, M; Karcz, T; Keeri, AR; Koczurkiewicz, P; Krawczyk, M; Kurczab, R; Lamaty, F; Latacz, G; Malikowska-Racia, N; Olejarz-Maciej, A; Partyka, A; Pęgiel, J; Pietruś, W; Piska, K; Popik, P; Satała, G; Trybała, W; Walczak, M; Zajdel, P | 1 |
| Chen, JJ; Fernandez, HH | 1 |
| Liguori, C; Mercuri, NB; Pierantozzi, M; Ruffini, R; Stefani, A | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Parambi, DGT | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Alborghetti, M; Bianchini, E; De Carolis, L; Della Gatta, F; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
| Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M | 1 |
5 review(s) available for safinamide and rasagiline
| Article | Year |
|---|---|
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
22 other study(ies) available for safinamide and rasagiline
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
Topics: Cell Survival; Chromones; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
Topics: Benzene Derivatives; Binding Sites; Blood-Brain Barrier; Drug Discovery; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxadiazoles; Sensitivity and Specificity | 2017 |
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
Topics: Alanine; Benzylamines; Chromones; Clorgyline; Coumarins; Humans; Indans; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline; Structure-Activity Relationship | 2017 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
Topics: Binding Sites; Catalytic Domain; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenols; Receptors, Histamine H3; Structure-Activity Relationship | 2018 |
(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
Topics: Benzamides; Blood-Brain Barrier; Cerebral Cortex; Models, Neurological; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Permeability; Structure-Activity Relationship | 2019 |
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Amides; Cell Proliferation; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imines; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
Topics: Alkaloids; Benzodioxoles; Caco-2 Cells; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
Topics: Antiparkinson Agents; Bromides; Coordination Complexes; Humans; Indazoles; Metals; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Protein Binding; Small Molecule Libraries; Structure-Activity Relationship; Tyramine | 2021 |
4-Oxoquinolines and monoamine oxidase: When tautomerism matters.
Topics: 4-Quinolones; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Indenes; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Sulfhydryl Compounds | 2021 |
Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
Topics: Cell Line; Chromones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2021 |
Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
Topics: Animals; Brain; Fluorine; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Rats | 2022 |
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Sleep; Sleep Wake Disorders; Surveys and Questionnaires | 2018 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies | 2021 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On.
Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline | 2023 |